Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
387 questions in 55 reviews · Common Mental Disorders
current versionsNo studies 387 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Escitalopram vs placebo Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | NR | No studies |
Escitalopram vs placebo Quality of life at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo Functional disability at 3 months ‐ not measured · adults experiencing acute traumatic stress symptoms Early pharmacological interventions for prevention of post‐traumatic stress disorder (PTSD) in individuals… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Psychosocial intervention vs control Functioning at · promoting the mental health of people living in LMICs affected by humanitarian crises (adults) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Psychosocial intervention vs control Prosocial behaviour at study endpoint ‐ not measured · promoting the mental health of people living in LMICs affected by humanitarian crises (adults) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Psychosocial intervention vs control Prosocial behaviour at · promoting the mental health of people living in LMICs affected by humanitarian crises (adults) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Psychosocial intervention vs control Functioning at study endpoint ‐ not measured · promoting the mental health of people living in LMICs affected by humanitarian crises (adults) Psychological and social interventions for the promotion of mental health in people living in low‐ and… (2024) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Mental Health First Aid (MHFA) training vs control Mental health service usage ‐ not measured · improving mental health and wellbeing Mental Health First Aid as a tool for improving mental health and well‐being (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Mental Health First Aid (MHFA) training vs control Adverse effects of MHFA ‐ not measured · improving mental health and wellbeing Mental Health First Aid as a tool for improving mental health and well‐being (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Mental Health First Aid (MHFA) training vs alternative mental health literacy interventions Individual mental health ‐ not measured · improving mental health and wellbeing Mental Health First Aid as a tool for improving mental health and well‐being (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Mental Health First Aid (MHFA) training vs alternative mental health literacy interventions Mental health service usage ‐ not measured · improving mental health and wellbeing Mental Health First Aid as a tool for improving mental health and well‐being (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Mental Health First Aid (MHFA) training vs alternative mental health literacy interventions Adverse effects of MHFA ‐ not measured · improving mental health and wellbeing Mental Health First Aid as a tool for improving mental health and well‐being (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Mental Health First Aid (MHFA) training vs alternative intervention Individual mental health ‐ not measured · improving mental health and wellbeing Mental Health First Aid as a tool for improving mental health and well‐being (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Mental Health First Aid (MHFA) training vs alternative intervention Mental health service usage ‐ not measured · improving mental health and wellbeing Mental Health First Aid as a tool for improving mental health and well‐being (2023) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table ‐ Mental Health First Aid (MHFA) training vs alternative intervention Adverse effects of MHFA ‐ not measured · improving mental health and wellbeing Mental Health First Aid as a tool for improving mental health and well‐being (2023) · Cochrane | no estimate extracted | NR | No studies |
Comparison 1: Alpha‐blockers vs placebo Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85) Pharmacotherapy for post traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Comparison 3: MAOIs vs placebo Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85) Pharmacotherapy for post traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Comparison 5: SNRIs vs placebo Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85) Pharmacotherapy for post traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs placebo Gambling expenditure ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs placebo Gambling frequency ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs placebo Time spent gambling ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Atypical antipsychotics vs placebo Functional impairment ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs opioid antagonists Gambling expenditure ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs opioid antagonists Gambling frequency ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs opioid antagonists Time spent gambling ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs opioid antagonists Functional impairment ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs mood stabilisers Gambling expenditure ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs mood stabilisers Gambling frequency ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs mood stabilisers Time spent gambling ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs mood stabilisers Functional impairment ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs mood stabilisers Gambling symptom severity ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs mood stabilisers Gambling expenditure ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs mood stabilisers Gambling frequency ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs mood stabilisers Time spent gambling ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs mood stabilisers Functional impairment ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs mood stabilisers Responder status ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo PTSD severity at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Propranolol vs placebo Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs placebo Dropout due to adverse events at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs placebo Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs placebo Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo Dropout due to adverse events at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo PTSD rate at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Hydrocortisone vs placebo Quality of life at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Propranolol vs placebo Dropout due to adverse events at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Propranolol vs placebo Functional disability at 3 months ‐ not measured · adults (aged 18 and older) exposed to a traumatic event Early pharmacological interventions for universal prevention of post‐traumatic stress disorder (PTSD) (2022) · Cochrane | no estimate extracted | NR | No studies |
Antipsychotic vs placebo Change in depression severity from baseline · adults with psychotic depression Pharmacological treatment for psychotic depression (2021) · Cochrane | no estimate extracted | NR | No studies |
Antipsychotic vs placebo Quality of life · adults with psychotic depression Pharmacological treatment for psychotic depression (2021) · Cochrane | no estimate extracted | NR | No studies |
Antipsychotic vs placebo Dropouts due to adverse effects · adults with psychotic depression Pharmacological treatment for psychotic depression (2021) · Cochrane | no estimate extracted | NR | No studies |